Updating results

Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

Evidence-based recommendations on secukinumab (Cosentyx) for ankylosing spondylitis (spondyloartritis) that has not responded well enough to conventional

Technology appraisal guidance Published September 2016

Miniature lens system implantation for advanced age-related macular degeneration (IPG565)

Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration (AMD)

Interventional procedures guidance Published September 2016

Transition between inpatient mental health settings and community or care home settings (NG53)

This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.

NICE guideline Published August 2016

Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults

Technology appraisal guidance Published August 2016

Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases

Technology appraisal guidance Published August 2016

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had..

Technology appraisal guidance Published August 2016

Bosutinib for previously treated chronic myeloid leukaemia (TA401)

Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults

Technology appraisal guidance Published August 2016

Extracorporeal carbon dioxide removal for acute respiratory failure (IPG564)

Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure in adults

Interventional procedures guidance Published August 2016

Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published August 2016

Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

Evidence-based recommendations on cabazitaxel (Jevtana) for prostate cancer that has come back after it was treated with docetaxel

Technology appraisal guidance Published May 2016 Last updated August 2016

Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults

Technology appraisal guidance Published April 2016 Last updated July 2016

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Evidence-based recommendations on nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for treating advanced melanoma (skin cancer)

Technology appraisal guidance Published July 2016

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)

Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia (AML) with more than 30% bone marrow blasts

Technology appraisal guidance Published July 2016

Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del..

Technology appraisal guidance Published July 2016

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel

Technology appraisal guidance Published June 2012 Last updated July 2016

Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation (IPG563)

Evidence-based recommendations on percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation (AF) in adults

Interventional procedures guidance Published July 2016

Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

Evidence-based recommendations on belimumab (Benlysta) as an add-on treatment for active autoantibody-positive systemic lupus erythematosus

Technology appraisal guidance Published June 2016

Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma with a BRAF V600 mutation

Technology appraisal guidance Published June 2016

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Technology appraisal guidance Published June 2016

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Technology appraisal guidance Published June 2016

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Technology appraisal guidance Published June 2016

Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules (IPG562)

Evidence-based recommendations on ultrasound-guided percutaneous radiofrequency ablation for treating benign thyroid nodules in adults

Interventional procedures guidance Published June 2016

Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting (IPG561)

Evidence-based recommendations on transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting

Interventional procedures guidance Published June 2016

Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects (IPG560)

Evidence-based recommendations on microstructural scaffold (patch) insertion without autologous cell implantation for repairing chrondral knee defects

Interventional procedures guidance Published June 2016

Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

Evidence-based recommendations on ceritinib (Zykadia) for advanced anaplastic lymphoma kinase positive non-small-cell lung cancer...

Technology appraisal guidance Published June 2016

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) for treating type 2 diabetes in adults

Technology appraisal guidance Published May 2016

Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (IPG559)

Evidence-based recommendations on transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine

Interventional procedures guidance Published May 2016

Biodegradable subacromial spacer insertion for rotator cuff tears (IPG558)

Evidence-based recommendations on biodegradable subacromial spacer insertion for rotator cuff tears in the shoulder

Interventional procedures guidance Published May 2016

Endovenous mechanochemical ablation for varicose veins (IPG557)

Evidence-based recommendations on endovenous mechanochemical ablation for treating varicose veins

Interventional procedures guidance Published May 2016

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx), paclitaxel, trabectedin (Yondelis) and gemcitabine...

Technology appraisal guidance Published April 2016

Percutaneous transforaminal endoscopic lumbar discectomy for sciatica (IPG556)

Evidence-based recommendations on percutaneous transforaminal endoscopic lumbar discectomy for sciatica

Interventional procedures guidance Published April 2016

Percutaneous interlaminar endoscopic lumbar discectomy for sciatica (IPG555)

Evidence-based recommendations on percutaneous interlaminar endoscopic lumbar discectomy for treating sciatica

Interventional procedures guidance Published April 2016

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (IPG554)

Evidence-based recommendations on balloon pulmonary angioplasty for treating chronic thromboembolic pulmonary hypertension

Interventional procedures guidance Published April 2016

Microwave ablation for treating liver metastases (IPG553)

Evidence-based recommendations on microwave ablation for treating liver metastases (cancer)

Interventional procedures guidance Published April 2016

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction

Technology appraisal guidance Published April 2016

Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

Evidence-based recommendations on ruxolitinib (Jakavi) for treating disease-related splenomegaly or symptoms in adults with myelofibrosis

Technology appraisal guidance Published March 2016

Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552)

Evidence-based recommendations on transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine

Interventional procedures guidance Published March 2016

Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis (IPG551)

Evidence-based recommendations on corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery for chronic rhinosinusitis

Interventional procedures guidance Published March 2016

Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia (IPG550)

Evidence-based recommendations on endoscopic carbon dioxide laser cricopharyngeal myotomy for relieving oropharyngeal dysphagia (swallowing difficulties)

Interventional procedures guidance Published March 2016

Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

Technology appraisal guidance Published April 2001 Last updated March 2016

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

Technology appraisal guidance Published February 2016

Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death (IPG549)

Evidence-based recommendations on normothermic extracorporeal heart preservation for transplantation following donation after brainstem death

Interventional procedures guidance Published February 2016

Mechanical clot retrieval for treating acute ischaemic stroke (IPG548)

Evidence-based recommendations on mechanical blood clot retrieval for treating acute ischaemic stroke

Interventional procedures guidance Published February 2016

Endovascular aneurysm sealing for abdominal aortic aneurysm (IPG547)

  March 2019: We have withdrawn the guidance because the CE mark for the Nellix Endovascular Aneurysm Sealing (EVAS) System has been withdrawn. Endologix is recalling unused stock. The MHRA recommends enhanced patient surveillance (see MDA/2019/002) because of a high risk of the graft failing beyond 2 years after implantation.

Interventional procedures guidance Published February 2016

Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction (IPG546)

Evidence-based recommendations on angioplasty and stenting to treat peripheral arterial disease (PAD) causing refractory erectile dysfunction

Interventional procedures guidance Published February 2016

Transition from children's to adults' services for young people using health or social care services (NG43)

This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.

NICE guideline Published February 2016

Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

Technology appraisal guidance Published February 2016

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

Technology appraisal guidance Published February 2016

Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)

NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…

Technology appraisal guidance Published January 2016

Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Technology appraisal guidance Published January 2016